Hunan Warrant the 91st API China 2024 Exhibition Ended Successfully

By HWCPharm | Updated: 2024-10-18 09:55:01

    After the CPHI in Milan, Italy, Hunan Warrant Chiral Pharmaceutical Co., Ltd., continues to attend the API exihibition hold in Xi’an City in China from Oct. 16th ~18th with booth No. 5A06. During this API China Exihibition, over 1000 companies from the industry of active pharmaceutical ingredients, intermediates, excipients, packaging materials and equipment gather together in the beautiful ancient city Xi’an.

 

We greeted many new and old customers from different regions to negotiate business. 

On October 18th, the 91st API China ended successfully at Xi'an International Convention and Exhibition Center. 

    Hunan Warrant mainly focus on developing the products in the fields of digestive system, respiratory system, anti-infection and cardiovascular system. Almost 60 APIs have been registered in China, 3 chemical APIs have obtained the registration certificate from South Korea MFDS, and 2 APIs are undergoing the evaluation of US FDA. This year, the producs Lanthanum Carbonate, Benidipine Hydrochloride, Ibuprofen Arginine, Ipratropium Bromide passed the GMP compliance inspection and they are all available for commercial. At present, 92 projects are under R&D in the company, where 9 projects are for international registration. All of these attract many old and new customers to our booth. The old customers are glad to cooperate with us since we can provide products with good quality, considerate service and complete technical documents. We looking forward to cooperate with many more customers to further expand the market share of our advantageous APIs and to reach the goal of forming resource integration, mutual trust and win-win strategic partners with customers.